Integra LifeSciences Holdings Co. (NASDAQ:IART) Receives Average Rating of “Hold” from Brokerages

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have been assigned a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a sell recommendation, two have given a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $45.00.

IART has been the subject of several analyst reports. Wells Fargo & Company raised shares of Integra LifeSciences from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $40.00 to $49.00 in a research note on Tuesday, December 5th. StockNews.com raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Thursday. Truist Financial decreased their price target on shares of Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating for the company in a research note on Friday, March 1st. Finally, JMP Securities decreased their price target on shares of Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating for the company in a research note on Thursday, February 29th.

Integra LifeSciences Price Performance

NASDAQ IART opened at $35.45 on Monday. The business’s fifty day moving average price is $39.35 and its 200-day moving average price is $39.68. The stock has a market capitalization of $2.79 billion, a price-to-earnings ratio of 42.71, a PEG ratio of 1.07 and a beta of 1.13. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.45 and a quick ratio of 2.18. Integra LifeSciences has a 1-year low of $33.24 and a 1-year high of $59.33.

Integra LifeSciences (NASDAQ:IART) last announced its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.01). The company had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s revenue for the quarter was down .3% compared to the same quarter last year. During the same period in the prior year, the business posted $0.94 earnings per share. On average, equities analysts predict that Integra LifeSciences will post 3.19 earnings per share for the current year.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors have recently modified their holdings of the company. Raymond James & Associates raised its stake in Integra LifeSciences by 24.5% during the first quarter. Raymond James & Associates now owns 40,457 shares of the life sciences company’s stock valued at $2,600,000 after buying an additional 7,971 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in Integra LifeSciences by 33.4% in the first quarter. MetLife Investment Management LLC now owns 47,096 shares of the life sciences company’s stock worth $3,026,000 after purchasing an additional 11,796 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in Integra LifeSciences by 10.5% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 26,696 shares of the life sciences company’s stock worth $1,715,000 after purchasing an additional 2,546 shares during the period. Great West Life Assurance Co. Can boosted its holdings in Integra LifeSciences by 8.0% in the first quarter. Great West Life Assurance Co. Can now owns 40,012 shares of the life sciences company’s stock worth $2,643,000 after purchasing an additional 2,969 shares during the period. Finally, Yousif Capital Management LLC boosted its holdings in Integra LifeSciences by 6.5% in the first quarter. Yousif Capital Management LLC now owns 40,207 shares of the life sciences company’s stock worth $2,584,000 after purchasing an additional 2,466 shares during the period. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.